Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily Dosing in Kidney Transplant Recipients
NCT02426502Active, not recruiting
- Sponsor
- University of British Columbia
- Start
- Apr 2016
- Primary completion
- Aug 2022
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by University of British Columbia. Primary endpoints: Number of patients not meeting safety criteria at 1 year and Number of patients successfully converted to a once daily dosing regimen at 2 years. Started Apr 2016; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02426502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426502.